Trial of VLTS-589 in Subjects With Intermittent Claudication
NCT ID: NCT00068133
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2003-06-30
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasmid based Gene Transfer product-VLTS-589
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must give informed consent,
* Current medical history of peripheral arterial disease, which includes the following symptoms: leg pain, leg discomfort or leg weakness
Exclusion Criteria
* History of cancer (except skin cancer) within the past 5 years,
* Participation in another clinical trial within 30 days of enrollment in this trial,
* Unwillingness or inability to comply with all study requirements
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Valentis
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology Pc
Birmingham, Alabama, United States
Arizona Heart Institute
Phoenix, Arizona, United States
Access Clinical Trials-Cardiovascular Research
Beverly Hills, California, United States
Jacksonville Heart Center
Jacksonville, Florida, United States
Heart Specialists of Sarasota Clinical Research Center
Sarasota, Florida, United States
American Cardiovascular Research Institute
Atlanta, Georgia, United States
Rush Presbyterian St. Luke's Medical Center
Chicago, Illinois, United States
Prairie Heart Institution at St. John's Hospital
Springfield, Illinois, United States
The Care Group
Indianapolis, Indiana, United States
New Orleans Center for Clinical Research
New Orleans, Louisiana, United States
Androscoggin Cardiology Associates
Auburn, Maine, United States
University of Michigan Health Systems
Ann Arbor, Michigan, United States
Minneapolis Heart Institution Foundation
Minneapolis, Minnesota, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
St. Vincent's Hospital
New York, New York, United States
Duke Clinical Research Institute
Durham, North Carolina, United States
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
The Methodist Hospital
Houston, Texas, United States
Daniel Gottleib, MD
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VLTS-589-121
Identifier Type: -
Identifier Source: org_study_id